Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer

Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancerCombining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer, Published online: 30 January 2019; doi:10.1038/s41388-019-0708-7Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer

Source: Oncogene - January 30, 2019 Category: Cancer & Oncology Authors: Joan Cao Zhou Zhu Hui Wang Timothy C. Nichols Goldie Y. L. Lui Shibing Deng Paul A. Rejto Todd VanArsdale James S. Hardwick Scott L. Weinrich Ping Wei Source Type: research